These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 19056447)

  • 41. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations.
    Furuya Y; Regner M; Lobigs M; Koskinen A; Müllbacher A; Alsharifi M
    J Gen Virol; 2010 Jun; 91(Pt 6):1450-60. PubMed ID: 20147516
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.
    Guo Y; He L; Song N; Li P; Sun S; Zhao G; Tai W; Jiang S; Du L; Zhou Y
    Microbes Infect; 2017 Dec; 19(12):641-647. PubMed ID: 28903071
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).
    Sipo I; Knauf M; Fechner H; Poller W; Planz O; Kurth R; Norley S
    Vaccine; 2011 Feb; 29(8):1690-9. PubMed ID: 21195079
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens.
    Zhang X; Liu M; Liu C; Du J; Shi W; Sun E; Li H; Li J; Zhang Y
    Intervirology; 2011; 54(5):290-9. PubMed ID: 21228535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination.
    van Maurik A; Sabarth N; Dacho HS; Brühl P; Schwendinger M; Crowe BA; Noel Barrett P; Kistner O; Keith Howard M
    Vaccine; 2010 Feb; 28(7):1778-85. PubMed ID: 20018265
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
    Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
    J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
    Tao W; Hurst BL; Shakya AK; Uddin MJ; Ingrole RS; Hernandez-Sanabria M; Arya RP; Bimler L; Paust S; Tarbet EB; Gill HS
    Antiviral Res; 2017 May; 141():62-72. PubMed ID: 28161578
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel M2e-multiple antigenic peptide providing heterologous protection in mice.
    Wen F; Ma JH; Yu H; Yang FR; Huang M; Zhou YJ; Li ZJ; Wang XH; Li GX; Jiang YF; Tong W; Tong GZ
    J Vet Sci; 2016 Mar; 17(1):71-8. PubMed ID: 27051342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
    Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
    Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
    Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
    Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles.
    Lee YT; Kim KH; Ko EJ; Kim MC; Lee YN; Hwang HS; Lee Y; Jung YJ; Kim YJ; Santos J; Perez DR; Kang SM
    Virology; 2019 Mar; 529():111-121. PubMed ID: 30685658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.
    Kim MC; Lee YN; Hwang HS; Lee YT; Ko EJ; Jung YJ; Cho MK; Kim YJ; Lee JS; Ha SH; Kang SM
    Vaccine; 2014 Oct; 32(44):5824-31. PubMed ID: 25171841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.